mAbxience automates bioprocess data with Genedata
Global CDMO mAbxience selected Genedata Bioprocess to automate and harmonize its end-to-end bioprocess development data, laying the groundwork for AI-driven analytics.
The Genedata Bioprocess platform will allow mAbxience to standardize data from different sources and formats, creating a single source of truth for bioprocess data. This will improve data quality, reduce manual data entry, and accelerate process development. mAbxience expects to use the platform to optimize its bioprocesses, improve product quality, and reduce manufacturing costs. The company also plans to leverage the platform's AI capabilities to develop predictive models for bioprocess performance. Genedata Bioprocess is designed to handle the complexity and volume of data generated during biopharmaceutical development and manufacturing. The platform supports a wide range of bioprocess workflows, including cell line development, upstream processing, downstream processing, and formulation.
